The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-(4-(1-(difluoromethyl)-3,5-dimethyl-1H-pyrazol-4-yl)-2-methylphenyl)-N-(imidazo[1,2-a]pyridin-6-ylmethyl)-N-methyl-1,3,4-oxadiazol-2-amine ID: ALA4877985
PubChem CID: 164628979
Max Phase: Preclinical
Molecular Formula: C24H23F2N7O
Molecular Weight: 463.49
Molecule Type: Unknown
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Cc1cc(-c2c(C)nn(C(F)F)c2C)ccc1-c1nnc(N(C)Cc2ccc3nccn3c2)o1
Standard InChI: InChI=1S/C24H23F2N7O/c1-14-11-18(21-15(2)30-33(16(21)3)23(25)26)6-7-19(14)22-28-29-24(34-22)31(4)12-17-5-8-20-27-9-10-32(20)13-17/h5-11,13,23H,12H2,1-4H3
Standard InChI Key: BWGPQCFMXBFDLN-UHFFFAOYSA-N
Molfile:
RDKit 2D
34 38 0 0 0 0 0 0 0 0999 V2000
13.8382 -24.8599 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.8382 -24.0327 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.5463 -23.6182 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.2584 -24.0350 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.2584 -24.8599 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.5463 -25.2683 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.9723 -25.2736 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.6875 -24.8621 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.4014 -25.2756 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.4853 -26.0961 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.2919 -26.2689 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
18.7056 -25.5549 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.1543 -24.9411 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
19.5262 -25.4698 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.0079 -26.1392 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.8278 -26.0545 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.1652 -25.3006 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.6765 -24.6307 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.8583 -24.7187 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.3716 -24.0524 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.9857 -25.2144 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.5373 -25.8267 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.2910 -25.4911 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.2048 -24.6704 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
22.3978 -24.4990 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.0618 -23.7455 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.8179 -24.1184 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.6026 -24.3733 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
23.6464 -23.3114 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
22.3659 -26.6336 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.6875 -24.0370 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.3711 -22.8167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.5545 -22.7357 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.2253 -23.4873 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
2 3 1 0
4 3 1 0
5 4 2 0
6 5 1 0
1 6 2 0
5 7 1 0
7 8 1 0
8 9 1 0
9 10 2 0
10 11 1 0
11 12 2 0
12 13 1 0
13 9 1 0
12 14 1 0
14 15 2 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
19 20 1 0
17 21 1 0
21 22 1 0
22 23 2 0
23 24 1 0
24 25 1 0
25 21 2 0
25 26 1 0
24 27 1 0
27 28 1 0
27 29 1 0
22 30 1 0
8 31 1 0
3 32 1 0
32 33 2 0
33 34 1 0
34 2 2 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 463.49Molecular Weight (Monoisotopic): 463.1932AlogP: 5.20#Rotatable Bonds: 6Polar Surface Area: 77.28Molecular Species: NEUTRALHBA: 8HBD: ┄#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 6.32CX LogP: 4.13CX LogD: 4.10Aromatic Rings: 5Heavy Atoms: 34QED Weighted: 0.34Np Likeness Score: -1.71
References 1. McCoull W, Boyd S, Brown MR, Coen M, Collingwood O, Davies NL, Doherty A, Fairley G, Goldberg K, Hardaker E, He G, Hennessy EJ, Hopcroft P, Hodgson G, Jackson A, Jiang X, Karmokar A, Lainé AL, Lindsay N, Mao Y, Markandu R, McMurray L, McLean N, Mooney L, Musgrove H, Nissink JWM, Pflug A, Reddy VP, Rawlins PB, Rivers E, Schimpl M, Smith GF, Tentarelli S, Travers J, Troup RI, Walton J, Wang C, Wilkinson S, Williamson B, Winter-Holt J, Yang D, Zheng Y, Zhu Q, Smith PD.. (2021) Optimization of an Imidazo[1,2-a ]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy., 64 (18.0): [PMID:34478292 ] [10.1021/acs.jmedchem.1c00920 ]